Clinical Trial Update: Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study [Phase 2]

View source ↗

Summary

Phase 2 RELIEF-NAFLD trial update evaluating lisinopril to prevent progression of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis; study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Lisinopril (Lisinopril)

Snippet

Sponsor: Northwestern University | Conditions: Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING